New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders

被引：14

作者：

Matutes, E

机构：

[1] Royal Marsden Hosp, Acad Dept Haematol & Cytogenet, London SW3 6JJ, England

[2] Royal Marsden Hosp, Inst Canc Res, London SW3 6JJ, England

来源：

JOURNAL OF CLINICAL PATHOLOGY | 2002年 / 55卷 / 03期

关键词：

D O I：

10.1136/jcp.55.3.180

中图分类号：

R36 [病理学];

学科分类号：

100104 [病理学与病理生理学];

摘要：

Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative disorders. In addition to the diagnostic value, the expression of certain markers such as p53 or CD38 provides relevant prognostic information to the clinician. Beyond their diagnostic and prognostic value, immunological markers play a major role in the detection of minimal residual disease, enabling the clinician to estimate more accurately the response to chemotherapy. Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed.

引用

页码：180 / 183

页数：4

共 46 条

[1]

An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia [J].